Americhem Acquires Noble Biomaterials in Smart Fabric Play

CUYAHOGA FALLS, Ohio – October 27, 2026

In an era where technological resilience and supply chain security are paramount, the materials that wrap our soldiers, shield our medical devices, and protect our decentralized data networks are becoming as complex as the silicon chips they house. This shifting landscape was brought into sharp focus today with the announcement that Americhem, a global designer and manufacturer of custom polymer solutions, has acquired Noble Biomaterials.

The transaction integrates the Scranton, Pennsylvania-based advanced materials company—best known for its proprietary antimicrobial and conductive soft surface technologies—into Americhem’s expansive worldwide manufacturing platform. While financial terms of the deal were not publicly disclosed, the acquisition represents a calculated pivot for the Ohio-based polymer giant. By absorbing Noble’s flagship platforms, including IONIC+®, X-STATIC®, and CIRCUITEX®, the combined entity is positioning itself at the lucrative intersection of specialty chemicals, wearable health tech, and next-generation defense gear.

For observers of industrial strategy, the move signals a broader transition in the advanced materials sector: the race to control the vertically integrated production of mission-critical, high-barrier technologies.

Moving Up the Value Chain: A Private Equity Playbook

The acquisition cannot be viewed in a vacuum; it is a textbook execution of a private equity growth strategy in a tightening market. Pritzker Private Capital (PPC), which agreed to acquire a majority stake in Americhem, has been instrumental in driving this expansion.

The broader private equity landscape for chemical companies has seen a notable contraction in recent years, with overall deal value dropping from a peak of nearly $20 billion earlier in the decade to roughly $5.9 billion. However, this macro-level cooling masks a fierce, ongoing bidding war for specialty and niche chemical businesses. Investors are increasingly pivoting away from pure financial engineering toward operational improvements and strategic add-on acquisitions. Today, add-on deals like Americhem’s purchase of Noble account for nearly a third of all transactions in the North American chemicals sector.

“In a contracted chemical M&A market, the premium is entirely on defensible moats and proprietary intellectual property,” noted one industry M&A analyst familiar with the transaction. “Noble’s status as a sole-source military supplier and its deep patent portfolio in metalized fibers provide exactly the kind of high-margin, sticky revenue that private equity sponsors are looking to bolt onto larger platforms.”

Kaitlyn Desai, Principal at PPC, echoed this strategic alignment in the official announcement. “We believe Noble Biomaterials is an exciting addition, and its technology and market focus align well with Americhem’s strategic direction,” she said. “This acquisition reinforces our conviction in Americhem’s growth strategy and the strength of its capabilities.”

The Smart Fabric Horizon and Defense Integration

To understand the true value of this acquisition, one must look closely at Noble’s CIRCUITEX® technology. As the global power grid decentralizes and electronic warfare becomes a standard operational domain, the need to protect sensitive electronics from electromagnetic interference (EMI) and radio frequency interference (RFI) has skyrocketed.

CIRCUITEX is engineered for multi-spectral energy management, capable of moving electrical energy and data through soft surface materials without wires. More importantly, its proprietary material technology can scatter and shield energy waves, reducing power by up to 100dB and remaining effective from 30 MHz through 30 GHz. This level of protection far exceeds standard industry benchmarks and has cemented the Scranton-based firm as an essential sole-source technology supplier of medical and shielding components to the United States Military and the Department of State.

The defense applications are already yielding highly specialized products. Recently, Carrington Textiles unveiled “Stealth,” a fabric technology developed in collaboration with the acquired firm that utilizes the CIRCUITEX SIGMA platform. Engineered to mitigate the thermal signature of soldiers from battlefield sensors, the fabric provides broad-spectrum shortwave, medium, and long infrared thermal signature management.

By marrying Americhem’s massive masterbatch compounding scale with these conductive metal-bonded textiles, the newly formed powerhouse can accelerate the development of smart fabrics. This means everything from biometric monitoring garments for elite athletes to EMI-shielded tents that protect decentralized server nodes in combat zones can now be developed and scaled under one corporate umbrella.

Healthcare and the Antimicrobial Imperative

Beyond the battlefield, the acquisition aggressively targets the exploding market for medical infection control. The global antimicrobial coatings market is on a blistering growth trajectory, projected by some market intelligence firms to reach nearly $49 billion by the mid-2030s. This surge is driven by a heightened global awareness of healthcare-associated infections (HAIs) and increasingly stringent infection control regulations.

Silver-based antimicrobial coatings currently dominate this space due to their proven effectiveness, biocompatibility, and long-lasting protection. Noble’s X-STATIC and IONIC+ platforms are built entirely around this silver-ion technology.

Before the acquisition, Americhem was already a major player in producing the base polymers and color concentrates used in medical devices. Now, they own the proprietary functional additives that make those devices actively resistant to pathogens. This vertical integration allows them to offer turnkey solutions to medical device manufacturers, solving complex performance challenges where failure is not an option.

“This is an exciting step forward for Americhem as we continue to invest in high-growth, high-demand markets,” said John Richard, Chief Executive Officer of Americhem. “Noble Biomaterials brings exceptional capabilities in antimicrobial solutions, strong commercial relationships and a reputation for quality that aligns with our values. We will be better positioned to deliver specialized solutions at a global scale as we make strategic investments to grow in healthcare and aerospace and defense.”

Synergies on the Factory Floor

Operationally, the integration of the two companies presents a compelling synergy of scale and specialization. Americhem operates nine manufacturing plants globally, providing the sheer volume and distribution network necessary to take niche technologies to a worldwide audience.

Crucially, Noble Biomaterials maintains its domestic manufacturing and headquarters in Scranton, Pennsylvania. In an era where supply chain sovereignty is heavily scrutinized by federal procurement officers, maintaining a robust U.S. manufacturing base for mission-critical defense and healthcare materials is a significant competitive advantage. While post-acquisition consolidation is common in private equity roll-ups, the specialized nature of the Scranton facility’s metal-bonding processes suggests that retaining this domestic workforce will be vital to fulfilling existing federal contracts.

Joel Furey, Founder and Chief Commercial Officer of Noble Biomaterials, highlighted this complementary dynamic. “Americhem is the right partner for Noble Biomaterials’ next chapter, bringing complementary capabilities, global reach, scalable resources, and a customer-first culture that will drive lasting value,” Furey stated. “Our proprietary materials and brands will benefit from Americhem’s global scale and deep knowledge of polymer and fiber applications.”

As industries ranging from consumer electronics to aerospace increasingly demand materials that do more than just provide structure—materials that can conduct data, shield radiation, and kill bacteria—the traditional boundaries between textiles, polymers, and electronics are dissolving. Americhem’s absorption of Noble Biomaterials is a clear indicator that the future of advanced manufacturing belongs to those who can engineer and scale these multi-functional, resilient materials from the molecular level up to full commercial production.